Biogen
Statement: Global Alzheimer’s Platform Foundation Praises FDA for Aducanumab Approval
Patients and Doctors Deserve the Ability to Consider Whether Aducanumab Will Deliver the Best Medical Outcome and Quality of Life Washington, DC (June 7, 2021) – John Dwyer, President of the Global Alzheimer’s Platform Foundation (GAP), a patient-centric organization committed to accelerating the discovery of therapies for the treatment of Alzheimer’s, issued the following statement on […]
Read more »